AstraZeneca is delaying their delivery of some batches of the childhood nasal spray flu vaccine (Fluenz Tetra®) due to be delivered to PHE in November.
This is due to an ‘invalid’ test result in its routine quality testing process which need to be repeated before these batches of vaccine are released by the independent regulator. This is not related to the safety or the efficacy of the vaccine itself, which has passed all the other tests.
Although we anticipate that this issue will be resolved quickly; there will be an unavoidable delay to the release of some stock, which may have a knock-on effect on the release of vaccine through ImmForm.
It does not affect batches of the vaccine already distributed, or those currently available to order and use for the 2019/20 season.